Clinical trial
Efficacy and Safety of Imatinib in Scleroderma
NCT00479934 · University Hospital, Bordeaux, Other · Completed
Key facts
| NCT number | NCT00479934 |
|---|---|
| Title | Efficacy and Safety of Imatinib in Scleroderma |
| Official title | Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement. |
| Acronym | SCLEROGLIVEC |
| Lead sponsor | University Hospital, Bordeaux, Other |
| Collaborators | Ministry of Health, France Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Scleroderma, Localized, Systemic |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 28 |
| Start date | Dec 1, 2007 |
| Primary completion | Jun 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | May 30, 2007 |
| Last update posted | Mar 4, 2011 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: